SWOG clinical trial number
S0347

A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With Her-2 Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy – Phase III

0% Accrual
Accrual
0%
Closed
Phase
0% Accrual
Accrual
0%
Abbreviated Title
ADVANCED: Vinorelbine vs. Vinorelbine and Trastuzumab
Activated
12/15/2004
Closed
02/01/2006
Participants
NCORP, Members, Medical Oncologists, CTSU

Research committees

Breast Cancer

Treatment

Trastuzumab Vinorelbine tartrate

Other Clinical Trials

CTSU-A012301
SWOG Clinical Trial Number
S2212
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Activated
07/21/2023
31% Accrual
Accrual
31%
Open
Phase